Next Article in Journal / Special Issue
Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer
Previous Article in Journal
The Association between Plasma Omega-6/Omega-3 Ratio and Anthropometric Traits Differs by Racial/Ethnic Groups and NFKB1 Genotypes in Healthy Young Adults
Article Menu

Export Article

Open AccessReview
J. Pers. Med. 2019, 9(1), 14; https://doi.org/10.3390/jpm9010014

Autonomy Challenges in Epigenetic Risk-Stratified Cancer Screening: How Can Patient Decision Aids Support Informed Consent?

1
Department of Public Health, Erasmus MC, P.O. 2040, 3000 CA Rotterdam, The Netherlands
2
Department of Medical Ethics and Philosophy of Medicine, Erasmus MC, P.O. 2040, 3000 CA Rotterdam, The Netherlands
*
Author to whom correspondence should be addressed.
Received: 11 February 2019 / Accepted: 14 February 2019 / Published: 18 February 2019
(This article belongs to the Special Issue Risk-stratified Cancer Screening)
Full-Text   |   PDF [2045 KB, uploaded 27 February 2019]   |  

Abstract

Information of an individual’s epigenome can be useful in cancer screening to enable personalised decision making on participation, treatment options and further screening strategies. However, adding this information might result in complex risk predictions on multiple diseases, unsolicited findings and information on (past) environmental exposure and behaviour. This complicates informed consent procedures and may impede autonomous decision-making. In this article we investigate and identify the specific features of epigenetic risk-stratified cancer screening that challenge the current informed consent doctrine. Subsequently we describe current and new informed consent models and the principle of respect for autonomy and argue for a specific informed consent model for epigenetic risk-stratified screening programmes. Next, we propose a framework that guides the development of Patient Decision Aids (PDAs) to support informed consent and promote autonomous choices in the specific context of epigenetic cancer screening programmes. View Full-Text
Keywords: cancer screening programmes; epigenetics; risk prediction; patient autonomy; informed consent; patient decision aids cancer screening programmes; epigenetics; risk prediction; patient autonomy; informed consent; patient decision aids
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Alblas, M.; Schermer, M.; Vergouwe, Y.; Bolt, I. Autonomy Challenges in Epigenetic Risk-Stratified Cancer Screening: How Can Patient Decision Aids Support Informed Consent? J. Pers. Med. 2019, 9, 14.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top